stockrow
Friday 6 November 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
19.02
0.13
+0.69%
Follow NAMS
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
116.40 | 587.14 | 172.66 | 184.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(75.91) | (106.62) | (127.31) | (101.63) | |
P/B ratio |
4.79 | 6.62 | 5.86 | 6.08 | |
Price to Tangible BV |
4.79 | 6.63 | 5.86 | 6.08 | |
EV/Sales |
91.91 | 497.94 | 144.41 | 156.28 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.84) | (24.72) | (22.96) | (23.80) | |
EV/FCF |
(15.80) | (24.67) | (22.92) | (23.76) | |
Quick Ratio |
0.00 | 8.70 | 9.45 | 7.43 | |
Current Ratio |
11.76 | 9.03 | 9.76 | 7.88 | |
Net Debt/EBITDA |
0.00 | 9.80 | 10.92 | 9.67 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.01 | 0.03 | 0.03 | |
Operating CF/Net income |
2.29 | 0.61 | 0.63 | 0.55 | |
Capex/Depreciation |
(2.64) | (1.36) | (0.61) | (1.69) | |
Research and Development Expense of Revenue |
205.37% | 1,125.99% | 1,250.30% | 120,606.25% | |
Selling, General and Administrative Expense of Revenue |
125.21% | 726.61% | 771.41% | 85,681.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
65.31% | 496.65% | 592.17% | 43,821.88% | |
Graham Net Nets |
0.20 | 0.14 | 0.15 | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.95%) | (6.37%) | (5.59%) | (4.93%) | |
Free Cash Flow Yield |
(5.00%) | (3.44%) | (3.65%) | (3.56%) | |
Revenue per Share |
0.15 | 0.03 | 0.03 | 0.00 | |
Operating CF per Share |
(0.32) | (0.32) | (0.25) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.32) | (0.25) | (0.35) | |
Cash per Share |
0.00 | 5.15 | 5.24 | 5.38 | |
Shareholders Equity per Share |
5.08 | 5.12 | 5.47 | 5.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.08 | 5.12 | 5.47 | 5.77 | |
Free Cash Flow |
(39.95) | (39.29) | (30.64) | (40.97) | |
Working Capital |
615.01 | 586.23 | 590.62 | 589.91 | |
Capital Expenditures |
(0.18) | (0.08) | (0.04) | (0.10) | |
Net Current Asset Value |
614.96 | 586.18 | 590.62 | 589.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 3.13 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.13 | 5.66 | 7.09 | 6.86 | |
Average Assets |
737.21 | 759.78 | 775.53 | 816.95 | |
Average Common Equity |
679.43 | 704.96 | 721.29 | 720.47 |
Columns are period end dates · fundamentals updated 4 Nov 2026